Gilead Company Kite Says FDA Oks RVV Manufacturing Facility In California For Commercial Production
(RTTNews) - Biopharmaceutical company Kite, a Gilead Sciences, Inc. (GILD) company, announced Monday that the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.
Viral vectors are key components needed to manufacture Kite's cell therapies to treat certain blood cancers. Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, augmenting its strong external supply partners.
The viral vector facility further strengthens the vertical integration of Kite's global CAR T-cell Therapy manufacturing network. CAR T-cell therapies are one-time treatments individually made starting from a patient's own white blood cells, called T-cells.
The Oceanside site is part of Kite's global commercial manufacturing network that includes facilities in El Segundo, California, Amsterdam, Netherlands, and a recently FDA-approved Maryland site.
For More Such Health News, visit rttnews.com
Gilead Recalls COVID-19 Drug Veklury For Injection
Kite Says Tecartus Shows Prolonged OS In Adults With Refractory B-cell Acute Lymphoblastic Leukemia
Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1
Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years
Hookipa Pharma Says Gilead Purchases Addl. 15 Mln Shares Of HOOKIPA For Total Stake Of About 19.4%
Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program
Gilead Exercises Option To License Nurix's Protein Degrader Molecule NX-0479
